Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Arcus Biosciences Inc’s stock clocked out at $10.06, up 4.03% from its previous closing price of $9.67. In other words, the price has increased by $4.03 from its previous closing price. On the day, 0.97 million shares were traded. RCUS stock price reached its highest trading level at $10.23 during the session, while it also had its lowest trading level at $9.74.
Ratios:
To gain a deeper understanding of RCUS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.50. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on February 26, 2025, Upgraded its rating to Buy and sets its target price to $24 from $18 previously.
On October 21, 2024, H.C. Wainwright started tracking the stock assigning a Neutral rating and target price of $20.
On October 08, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $29.Wells Fargo initiated its Overweight rating on October 08, 2024, with a $29 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 27 ’25 when KANEKO YASUNORI bought 20,000 shares for $10.06 per share. The transaction valued at 201,200 led to the insider holds 28,400 shares of the business.
ROSEN TERRY J bought 19,800 shares of RCUS for $201,465 on Feb 27 ’25. The Chief Executive Officer now owns 2,554,160 shares after completing the transaction at $10.18 per share. On Feb 18 ’25, another insider, GILEAD SCIENCES, INC., who serves as the 10% Owner of the company, bought 1,363,636 shares for $11.00 each. As a result, the insider paid 14,999,996 and bolstered with 31,424,760 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 1070695936 and an Enterprise Value of 289695616. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.09 while its Price-to-Book (P/B) ratio in mrq is 1.95. Its current Enterprise Value per Revenue stands at 1.106 whereas that against EBITDA is -0.883.
Stock Price History:
The Beta on a monthly basis for RCUS is 0.82, which has changed by -0.36045772 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, RCUS has reached a high of $18.98, while it has fallen to a 52-week low of $6.50. The 50-Day Moving Average of the stock is 9.33%, while the 200-Day Moving Average is calculated to be -11.21%.
Shares Statistics:
It appears that RCUS traded 976.60K shares on average per day over the past three months and 864950 shares per day over the past ten days. A total of 106.40M shares are outstanding, with a floating share count of 64.97M. Insiders hold about 38.95% of the company’s shares, while institutions hold 62.21% stake in the company. Shares short for RCUS as of 1753920000 were 8973712 with a Short Ratio of 9.19, compared to 1751241600 on 10974061. Therefore, it implies a Short% of Shares Outstanding of 8973712 and a Short% of Float of 12.9.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Arcus Biosciences Inc (RCUS) is currently being evaluated by 3.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$1.22, with high estimates of -$1.18 and low estimates of -$1.29.
Analysts are recommending an EPS of between -$3.59 and -$3.84 for the fiscal current year, implying an average EPS of -$3.71. EPS for the following year is -$4.45, with 3.0 analysts recommending between -$4.13 and -$5.01.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $20.25M. It ranges from a high estimate of $21M to a low estimate of $17.75M. As of the current estimate, Arcus Biosciences Inc’s year-ago sales were $48MFor the next quarter, 7 analysts are estimating revenue of $20.25M. There is a high estimate of $21M for the next quarter, whereas the lowest estimate is $17.75M.
A total of 9 analysts have provided revenue estimates for RCUS’s current fiscal year. The highest revenue estimate was $232.9M, while the lowest revenue estimate was $223.5M, resulting in an average revenue estimate of $228.93M. In the same quarter a year ago, actual revenue was $258MBased on 10 analysts’ estimates, the company’s revenue will be $146M in the next fiscal year. The high estimate is $283.67M and the low estimate is $58M.
